RxDoctor Payments DataLook up a doctor →

Nipun Arora, MD

Interventional Cardiology · Altamonte Springs, FLNPI 1437122660

Payments from drug & device makers

$354,896in general payments, 2019–2025

Across 431 payments — averaging $823.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$191K
  • Abbott$151K
  • Siemens Medical Solutions USA, Inc.$3K
  • Edwards Lifesciences$2K
  • Inari Medical, Inc.$1K
  • Cvrx, Inc.$1K
  • plus $5K from 36 others

What the payments were for

  • Consulting fees$12,00022%
  • Speaking & faculty fees$25,25046%
  • Travel & lodging$5,0389%
  • Food & beverage$12,32223%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$354,896 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$441,484
Medicare patients
1,096
Services billed
3,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban157$184,594
XareltoRivaroxaban31$39,855
JardianceEmpagliflozin26$32,956
Repatha SureclickEvolocumab22$31,527
EntrestoSacubitril/Valsartan21$25,083
BrilintaTicagrelor11$6,638
ClopidogrelClopidogrel Bisulfate165$1,904
Rosuvastatin Calcium105$1,527
Carvedilol120$1,428
Ezetimibe36$1,153
Atorvastatin Calcium119$1,017
Bumetanide17$1,010
Losartan Potassium110$980
Nifedipine ErNifedipine39$974
Prasugrel Hcl24$835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$214$184,594157 claims
Johnson & JohnsonXarelto$221$39,85531 claims
Boehringer IngelheimJardiance$104$32,95626 claims
NovartisEntresto$404$25,08321 claims
AstraZenecaBrilinta$73$6,63811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Altamonte Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →